Cwm LLC Purchases 27,894 Shares of BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Cwm LLC increased its stake in BioMarin Pharmaceutical Inc. by 46.4%, acquiring an additional 27,894 shares during the 2nd quarter, bringing their total holdings to 87,955 shares valued at approximately $4.8 million.
• Analyst reports show varied opinions on BioMarin, with UBS Group raising its price target to $114 and maintaining a "buy" rating, while Zacks Research downgraded the stock from "strong-buy" to "hold".
• BioMarin Pharmaceutical has a market capitalization of $10.17 billion and is characterized by a moderate buy rating among analysts, with an average target price of $93.26.

Cwm LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 46.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,955 shares of the biotechnology company's stock after acquiring an additional 27,894 shares during the quarter. Cwm LLC's holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth $25,000. Farther Finance Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 211 shares in the last quarter. Rise Advisors LLC bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $30,000. Brooklyn Investment Group grew its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $71,000. Institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

BMRN has been the subject of several recent analyst reports. UBS Group upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an "overweight" rating on the stock in a report on Tuesday, July 22nd. Guggenheim boosted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Weiss Ratings reissued a "sell (d+)" rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $93.26.

BioMarin Pharmaceutical Price Performance

BMRN opened at $52.95 on Friday. The company has a market capitalization of $10.17 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 0.67 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $55.74 and a 200-day moving average price of $57.67. BioMarin Pharmaceutical Inc. has a twelve month low of $51.56 and a twelve month high of $73.51.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.